Expert Highlights ‘Paradigm Shift’ Surrounding Testosterone Therapy for Metastatic Prostate CancerJanuary 13th 2023
During the 2022 Society for Urologic Oncology (SUO) Annual Meeting, an expert from the Baylor College of Medicine, discussed how perceptions around the use of testosterone therapy have evolved for patients with metastatic prostate cancer.
Investigational Treatment Approach Effective, Safe and Inexpensive in a Type of Prostate Cancer, Says ExpertDecember 31st 2022
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Multiple Molecular Mechanisms May Drive Responses to Investigational Prostate Cancer Treatment, Expert SaysDecember 29th 2022
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
‘Absolutely Important’ to Develop Better Ways to Predict Kidney Cancer Recurrence, Says ExpertDecember 28th 2022
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Why European Experts Cautiously Recommend Pembrolizumab to Treat High-Risk Kidney Cancer Following SurgeryDecember 27th 2022
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Urologists Should Make Patients With Metastatic Kidney Cancer Aware that not All Trials Have Positive Results, Says ExpertDecember 25th 2022
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
‘Interesting’ Research Continues to Assess the Role of Radiation in Management of Metastatic Kidney CancerDecember 21st 2022
Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.
Pembrolizumab Remains Effective for Years in a Bladder Cancer SubsetDecember 5th 2022
Long-term follow-up showed that the use of pembrolizumab monotherapy maintained durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with a bladder cancer subset.
Follow-Up Data Show Tazemetostat Remains Safe, Elicits Benefit in Patients With Prostate CancerDecember 2nd 2022
At a median follow-up of 17.4 months, half of the enrolled patients with metastatic castration-resistant prostate cancer experienced a decrease in PSA level from baseline following treatment with tazemetostat in combination with abiraterone acetate or enzalutamide.
Adding Blue Light Cystoscopy to Standard White Light Decreases Tumor Recurrence in a Type of Bladder CancerDecember 2nd 2022
Findings from an interim analysis of data show that the addition of blue light cystoscopy to conventional white light significantly improved clinical outcomes in a group of patients with non–muscle-invasive bladder cancer.
Novel PSMA-TRT-based Triplet Regimen Appears Effective in Prostate CancerDecember 2nd 2022
All patients with chemo-naïve metastatic castration-resistant prostate cancer experienced PSA decline, and half the cohort experienced a PSA decline greater than 50% after treatment with a novel PSMA-targeted radionuclide therapy.
Neoadjuvant Pembrolizumab Induces Survival Benefit and High Downstaging Rate in Cisplatin-Ineligible Bladder CancerDecember 1st 2022
Patients with cisplatin-ineligible muscle-invasive bladder cancer experienced a better rate of downstaging and improved survival benefit with neoadjuvant pembrolizumab prior to radical cystectomy vs immediate radical cystectomy.
PSMA Remains ‘Relevant’ But Needs to Be ‘Improved Upon’ for Treating Prostate CancerDecember 1st 2022
“With more potent agents, can we actually cure patients [with prostate cancer]? I'm not so sure about that…because of heterogeneity,” said an expert from NewYork-Presbyterian – Weill Cornell Medical Center in New York City. “So we'll see. But I think with combinations, maybe someday we're going to be able to get there.”
More Research is Needed to Determine How to Integrate Theranostics With Standard Therapies for Localized Prostate Cancer, Says ExpertDecember 1st 2022
Theranostics may fill an unmet need for a group of patients with high-risk localized prostate cancer, but more research is needed to identify how oncology providers can integrate it with the standard treatments, according to an expert from the University of Texas MD Anderson Cancer Center.
Prospective Data Establishing the Clinical Utility of Testing All Biomarkers in Advanced Bladder Cancer is Still Needed, Says ExpertDecember 1st 2022
With the increasing clinical use of circulating tumor DNA biomarker testing among community urologists, an expert from Tisch Cancer Institute at Mount Sinai in New York City suggests that more prospective data are needed to make the best decisions among patients with bladder cancer.
Ramaprasad Srinivasan, MD, PhD, on the Design of the Study of MK-6482 in VHL-Associated DiseaseDecember 14th 2020
Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.